Clinical Trials · NCT01530607

Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer

Name: Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Completed
Sponsor: King Faisal Specialist Hospital & Research Center
Enrollment: 416
Start date: Nov 2009
Locations: See registry
Primary endpoint: The study is to compare the rate of premature ovarian failure at two years following standard adjuvant or neoadjuvant chemotherapy

View Gonadorelin compound reference